0
0
NEW DELHI — As India faces a mounting public health crisis fueled by tobacco use, leading medical experts and policy researchers are calling for a critical regulatory shift: reclassifying higher-strength nicotine gums as over-the-counter (OTC) medications.
The move, aimed at making 4 mg nicotine gums as accessible as their 2 mg counterparts, seeks to align Indian policy with global standards. Proponents argue that lowering barriers to these smoking cessation aids is essential for the nearly 100 million smokers in India, the vast majority of whom struggle to quit without pharmacological support.
The Barrier to Quitting: Why Dosage Matters
For decades, Nicotine Replacement Therapy (NRT)—which includes gums, patches, and lozenges—has been the gold standard for treating tobacco dependence. In India, while 2 mg gums are available over the counter, the 4 mg variant—often necessary for heavy smokers—frequently falls under stricter prescription regulations.
“It is critical to separate fear from facts,” says Dr. Meenakshi N., a Family Physician and Public Health Specialist at Apollo Hospital, Noida. “Nicotine gums are not initiation products; they are therapeutic tools. Extensive global evidence shows that regulated NRT delivers controlled nicotine without exposure to the tar, carbon monoxide, or the 7,000 toxic chemicals present in cigarettes.”
The distinction between 2 mg and 4 mg is not merely a matter of preference but of clinical efficacy. According to the World Health Organization’s (WHO) 2024 Tobacco Cessation Guidelines, the 4 mg dose is a first-line treatment specifically recommended for smokers with high nicotine dependence. Without easy access to the appropriate dose, many smokers face intense withdrawal symptoms that lead to a quick relapse.
A Statistical Look at the Crisis
The scale of the challenge in India is staggering. Data from the Global Adult Tobacco Survey (GATS-2) indicates that India is home to over 100 million smokers. Perhaps more alarming is the success rate of those trying to quit:
-
98% of quit attempts in India fail when conducted without pharmacological assistance.
-
1.35 million Indians die annually due to tobacco-related illnesses.
-
50–70% increase in long-term quit rates is observed when using NRT compared to unaided attempts, according to a landmark 2021 Cochrane Review.
Despite these figures, current regulations can make it difficult for rural and low-income populations to obtain the higher-strength gums they need. Experts argue that requiring a prescription for a life-saving cessation tool—while cigarettes remain widely available at every street corner—creates a “regulatory paradox.”
Safety vs. Perception: Addressing the “Nicotine Fear”
A common hurdle in policy expansion is the “conflation” of nicotine with the harms of smoking. While nicotine is the addictive component of tobacco, it is not the primary cause of cancer or lung disease.
“Nicotine itself is not risk-free, but the harm profile of medicinal nicotine is dramatically lower than smoking,” explains Dr. Rajesh Madan, Senior Consultant Cardiologist at Max Hospital, Dwarka. He emphasizes that global safety data, including studies recognized by the U.S. Food and Drug Administration (FDA), show no meaningful increase in cardiovascular events associated with therapeutic NRT use, even among patients with existing heart disease.
Furthermore, the Drugs Technical Advisory Board (DTAB) in India has previously acknowledged the low abuse potential of oral NRTs. Unlike “novel” nicotine delivery systems like e-cigarettes or flavored pouches, medicinal gums have a slow-release mechanism that does not produce the “spike” in nicotine levels associated with recreational use or addiction initiation.
Global Precedent and Local Implications
India would not be alone in deregulating 4 mg nicotine gums. More than 100 countries—including the United Kingdom, United States, Canada, and Australia—allow both strengths to be sold over the counter.
“The global lesson is clear: easier access to regulated NRT reduces smoking prevalence,” says R. Benjamin, a Behavior Therapist and Psychologist at Shambhave Wellness. “Restricting therapeutic doses does not protect youth; it only prolongs tobacco addiction among adults.”
In the Indian context, experts point to Article 21 of the Constitution, which guarantees the right to health. They argue that by restricting access to essential medicines listed on the WHO Essential Medicines List, the current regulatory framework may inadvertently hinder the National Tobacco Control Programme (NTCP) goals and the United Nations’ Sustainable Development Goal (SDG) 3.4, which aims to reduce premature mortality from non-communicable diseases.
| Feature | Smoked Tobacco (Cigarettes) | Medicinal Nicotine Gum |
| Toxic Chemicals | 7,000+ (Tar, Lead, Arsenic) | Nicotine Only (Controlled dose) |
| Delivery Speed | Instant “hit” to the brain | Slow, steady absorption |
| Health Impact | Major cause of cancer/heart disease | Therapeutic aid for cessation |
| Regulation Goal | Reduction and elimination | Increased access for smokers |
The Path Forward
Public health experts are calling for a “risk-proportionate” regulatory approach. This involves:
-
Reinstating 4 mg gums under Schedule K exemptions of the Drugs and Cosmetics Rules to allow OTC sales.
-
Differentiating medicinal gums from recreational nicotine products to prevent confusion in policy-making.
-
Increasing public awareness about the safety and efficacy of NRT to combat the stigma surrounding nicotine use in a clinical setting.
As the debate continues, the consensus among clinicians remains firm: the greatest risk to public health is not the gum used to quit, but the cigarette that remains unlit because a smoker couldn’t access the help they needed.
References
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
